pSivida

pSivida is a leading provider of miniaturised, sustained-release drug delivery products and is continuing the evolution of these systems.

Formerly an ASX-listed company, pSivida's intellectual property portfolio consists of over 150 issued patents in countries including the US, Europe, Japan, China and Australia.

pSivida, a NASDAQ-listed company, is developing products designed to revolutionise treatments, with a primary focus in ophthalmology.